Followers | 11 |
Posts | 1359 |
Boards Moderated | 0 |
Alias Born | 08/23/2014 |
Wednesday, August 16, 2017 9:01:31 AM
I have not looked at the Temple situation, I just took from the AGM that the negotiated position is much better than before and they were pretty glad to have sorted it.
It is not something I give much time as I don't think it is the highest priority.
A short email to QS would give clarity if you need it.
Your right the company has spent a lot of money on a lot a products, and none has really come to market.
The company has a very narrow focus for sales.
Electra, Joule heat, smaller AOTs for upstream, plus many other potential applications are all on hold despite significant market potential.
AOT RnD is finished, sales is the only company focus.
AOT is currently the primary focus, and only on pipelines over 100,000 BOD
They don't want to sell it, just charge a price per barrel.
The price mentioned at the AGM as an example was .01c per barrel per treatment.
So a single pipeline moving 125,000BOD on that price would get charged $1250 per day on each single AOT if operated at maximum capacity.
12 months that $450k and delivered a full ROI to QSEP.
Then every year after $450k moves to profit.
What if the rates for some was .015c or .02c per barrel.
AOT can deliver a ROI in under 12 months comfortably
All money after that is profit.
They spoke of 2 numbers at the AGM
50-70 AOTs
50 units would be on those numbers around $22 million per year.
Income is unlikely to ever drop, once AOT is on, its money every year.
1% is considered a great efficiency in the oil and gas industry.
What an AOT does is superior to current practice.
Each month since Jason took over except June insiders have bought shares.
I think QSEPs potential is just starting to be seen.
Smile
Recent field tests with a crude oil pipeline fully confirm the theoretical results.
Recent QSEP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:39:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 01:05:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:52:03 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM